Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15896MR)

This product GTTS-WQ15896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15896MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13613MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ12888MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ697MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ1810MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ3551MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ6275MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ4704MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ9686MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW